Compare · JNJ vs RPRX
JNJ vs RPRX
Side-by-side comparison of Johnson & Johnson (JNJ) and Royalty Pharma plc (RPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and RPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 17.8x RPRX ($34.28B).
- Over the past year, JNJ is up 33.0% and RPRX is up 67.7% - RPRX leads by 34.7 points.
- JNJ has been more active in the news (16 items in the past 4 weeks vs 6 for RPRX).
- JNJ has more recent analyst coverage (25 ratings vs 12 for RPRX).
- Company
- Johnson & Johnson
- Royalty Pharma plc
- Price
- -
- -
- Market cap
- $610.38B
- $34.28B
- 1M return
- -5.45%
- +3.48%
- 1Y return
- +33.03%
- +67.68%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 16
- 6
- Recent ratings
- 25
- 12
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Latest RPRX
- Royalty Pharma declares fourth quarter 2026 dividend
- Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
- SEC Form 4 filed by Royalty Pharma plc
- Director Bassler Bonnie L was granted 642 units of Class A Ordinary Shares, increasing direct ownership by 0.81% to 79,823 units (SEC Form 4)
- EVP, Research & Investments Urist Marshall sold $238,813 worth of Class A Ordinary Shares (4,126 units at $57.88) as part of a pre-agreed trading plan, decreasing direct ownership by 50% to 4,126 units (SEC Form 4)
- EVP & Chairman, Partnering Hite Christopher sold $5,853,095 worth of Class A Ordinary Shares (100,000 units at $58.53) as part of a pre-agreed trading plan (SEC Form 4)
- Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
- Royalty Pharma to present at upcoming investor conferences
- Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
- EVP & Chairman, Partnering Hite Christopher sold $5,997,250 worth of Class A Ordinary Shares (100,000 units at $59.97) as part of a pre-agreed trading plan and gifted 16,800 units of Class A Ordinary Shares, decreasing direct ownership by 42% to 23,200 units (SEC Form 4)